14,498 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Aurora Private Wealth Inc.

Aurora Private Wealth Inc. acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,498 shares of the company's stock, valued at approximately $2,387,000.

A number of other large investors have also recently made changes to their positions in ZTS. MOKAN Wealth Management Inc. bought a new position in Zoetis in the first quarter worth about $1,184,000. Mattern Capital Management LLC lifted its stake in shares of Zoetis by 1.0% in the 1st quarter. Mattern Capital Management LLC now owns 52,370 shares of the company's stock valued at $8,623,000 after purchasing an additional 527 shares during the period. Mill Capital Management LLC grew its stake in Zoetis by 0.4% in the first quarter. Mill Capital Management LLC now owns 123,728 shares of the company's stock worth $20,372,000 after purchasing an additional 546 shares during the period. Cornerstone Wealth Group LLC raised its holdings in Zoetis by 12.7% in the first quarter. Cornerstone Wealth Group LLC now owns 2,257 shares of the company's stock worth $372,000 after purchasing an additional 254 shares in the last quarter. Finally, Vectors Research Management LLC purchased a new position in Zoetis during the first quarter valued at $201,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Up 0.3%

ZTS opened at $157.76 on Wednesday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. The stock's 50 day moving average price is $159.89 and its 200-day moving average price is $163.06. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The stock has a market cap of $70.23 billion, a price-to-earnings ratio of 28.32, a P/E/G ratio of 2.61 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter in the prior year, the company posted $1.38 EPS. Zoetis's quarterly revenue was up 1.4% on a year-over-year basis. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio is presently 35.91%.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president now owns 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ZTS shares. Piper Sandler raised their price target on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. UBS Group lowered their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Finally, Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Zoetis currently has a consensus rating of "Buy" and an average target price of $212.13.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.